Merck's Zetia cuts heart attack, stroke risk in long-awaited study
November 17, 2014 at 11:37 AM EST
CHICAGO, Nov 17 (Reuters) - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia significantly lowered the risk of heart attacks and strokes in high-risk heart patients when used with a highly effective statin.
